Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04066673
Recruitment Status : Not yet recruiting
First Posted : August 26, 2019
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Asmaa Mohammed Mohammed Tawfeek, Assiut University

Tracking Information
First Submitted Date August 21, 2019
First Posted Date August 26, 2019
Last Update Posted Date August 28, 2019
Estimated Study Start Date September 2019
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: August 21, 2019)
Intelligence Quotient assessment in autistic children by the Stanford-Binet Intelligence Scales, 5th Edition [ Time Frame: Baseline ]
assess the cognitive strengths and weaknesses of children with autism and the possible effect of age and IQ on Stanford-Binet Intelligence Scale, 5th Edition.
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.
Official Title Intelligence Quotient Assessment in Children With Autistic Spectrum Disorders.
Brief Summary The aim of this study is to assess the cognitive strengths and weaknesses of children with autism and the possible effect of age and IQ on Stanford-Binet Intelligence Scale, 5th Edition. Such analysis will help us for prompt and early intervention.
Detailed Description

Autism Spectrum Disorders (ASDs) are characterized by deficits in both social interaction and communication, as well as by restricted and repetitive patterns of behavior, and are a type of Pervasive Developmental Disorder (PDD). Intellectual disability (ID) is characterized by deficits in adaptive functioning, an intelligence quotient (IQ) that falls at least two standard deviations below average (i.e., below 70), and onset prior to adulthood (American Psychiatric Association, 2000).

Although ID is not a core symptom of ASD, there is an established relationship between the two constructs. Seventy percent of children with AD have a co-morbid diagnosis of ID (Bolte & Poustka, 2002; Fombonne, 2005). It has been suggested that many children who would have been diagnosed with ID in the past would today receive an ASD diagnosis, even with identical symptomatology (Lecavalier et al., in press).

The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores(Roid, 2003).. One of the updated features of the SB5 is the nonverbal component, in that close to half of the responses no longer require verbal answers (Coolican, Bryson & Zwaigenbaum, 2008).The Full Scale IQ is derived from the verbal and nonverbal scales, each with five subtests bearing the same names: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial Processing, and Working Memory.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Forty children will participate in the study, clinically diagnosed by CARS Scoring IQ will be assessed by Stanford-Binet Intelligence Scales, 5th Edition have autism .They will be recruited from children attending Assiut University Hospital.
Condition Autism Spectrum Disorder
Intervention Diagnostic Test: Stanford-Binet Intelligence Scale, 5th Edition
The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: August 21, 2019)
40
Original Estimated Enrollment Same as current
Estimated Study Completion Date October 2020
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age: from3 to18 years
  • Gender: both sexes will be included in the study
  • Clinical ASD diagnosis.
  • Full Scale test results available for SB5.

Exclusion Criteria:

  • 1- Age below 3years or above 18 years. 2- Mental Retardation due to other causes than autism. 3- Presence of other chronic illnesses affecting their quality of lives.
Sex/Gender
Sexes Eligible for Study: All
Ages 3 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers Not Provided
Contacts
Contact: Asmaa Mohammed Mohammed, Resident 01155096915 Asmaa_tawfeek@med.au.edu.eg
Contact: Prof. Mohamed Mahrous EL-Tellawy, Professor of pediatric 01003486595 Fahim.osman@med.au.edu.eg
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT04066673
Other Study ID Numbers IQ in Autism
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Asmaa Mohammed Mohammed Tawfeek, Assiut University
Study Sponsor Assiut University
Collaborators Not Provided
Investigators Not Provided
PRS Account Assiut University
Verification Date August 2019